Recent results from studies on Indena’s standardized extracts in oncology
Milan, December 2nd, 2009 – Pharmacological and clinical data for colorectal carcinoma chemoprevention on Indena’s standardized bilberry extract Mirtoselect® were presented by Professor Andreas Gescher from the University of Leicester (UK) at the 51st Annual Meeting of the Italian Cancer Society (SIC) in Sesto San Giovanni, Milano (November 23rd-24th, 2009) during the session of “Dietary Supplements and Nutraceuticals in the Management of Cancer”.
Following a study in preclinical carcinogenesis model suggesting that Mirtoselect® may prevent malignancies in the gastrointestinal tract, the first-in-human pilot clinical trial has been presented at the Congress. 25 patients with colorectal cancer (and scheduled to undergo resection of primary tumor or liver metastasis) received Mirtoselect® 1.4, 2.8 and 5.6 grams daily for 7 days before surgery. Anthocyanins and metabolites were measured in plasma and colorectal tissue. Mirtoselect® reduced tumor proliferation in colorectal tumor samples taken from all patients who received the product by 7% compared with pre-intervention values.
“We are pleased that professor Gescher decided to use our product for his research as result of its high level of standardization, chemical characterization and safety profile. These data, even if preliminary, showed that anthocyanins rich bilberry extract may induce beneficial pharmacodynamic changes to counter tumor development in patients” said Antonella Riva, Senior Research Scientist at Indena.
Indena at the 51st Annual Meeting of the Italian Cancer Society (SIC)
Results from 2 other studies with Indena’s extracts in oncology presented at SIC Congress confirmed the company’s active involvement in oncological research. Indena researchers in conjunction with major Italian research institutes, presented two new posters illustrating important aspects of the pre-clinical work on the novel antitumoral molecules from Brassicaceae sp and Macleaya sp. In particular, during the session of “novel therapeutics approaches”, a poster presented by the Mario Negri Institute in Milan suggested that the isothiocyanate produced from glucomoringin has significant antitumoral activity in myeloma models in vitro and in vivo. In another poster, presented by the Catholic University of the Sacred Heart, Rome, the alkaloid sanguinarine showed interesting antitumoral activity in mouse models of malignant melanoma. Those two posters, along with the particular attention the company is devoting to the use of standardized extracts from edible plants in cancer prevention, reflect the company’s active participation in oncological research.
Indena is the world's leading company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health food and cosmetics industries. Backed up by over 85 years of botanical experience, the key to Indena’s success is its intense research activity. The company has more than 150 primary patents and has published more than 700 scientific studies. Indena employs more than 700 staff, including 10% dedicated to full-time research activities carried out at Settala Research Center, near Milan. Indena also co-operates with the world's most prestigious universities and private research institutions. Headquartered in Milan, Indena has 5 production sites and 4 international branches throughout the world and manages distribution operations in more than 40 countries. The Company's experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMEA, and ESCOP, and work with all the main pharmacopoeias.